If you’re living with chronic graft-versus-host disease (GVHD) — or supporting someone who is — you know this condition rarely affects just one part of the body. When symptoms involve the skin, joints ...

The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

SEATTLE — March 5, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. March is the awareness month for colorectal cancer and multiple ...

Fred Hutch bone marrow transplant and GVHD expert Dr. Geoffrey Hill explains how a new approach has changed the BMT landscape, where research is headed next Now, more than 1.5 million transplants have ...

Equillium, Inc. (NASDAQ:EQ) released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host ...

Hematopoietic stem cell transplantation (HSCT) remains a vital treatment for a variety of haematologic malignancies and non‐malignant disorders. The procedure, involving the transfer of multipotent ...

Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock ...

MiNK Therapeutics receives an NIAID grant to develop iNKT cell therapies for preventing graft-versus-host disease in stem cell transplants. MiNK Therapeutics, Inc., a biopharmaceutical company ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...